Atlanta
Baxter International will begin construction in 2012 on a $1 billion biologics manufacturing complex in Atlanta. Accommodating over 1,500 employees, the facility will support the creation of advanced plasma-based therapeutics. Commercial production is expected to begin in 2018.
Source
